Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-04-26
2011-04-26
Gussow, Anne M. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S006120, C435S007230
Reexamination Certificate
active
07932044
ABSTRACT:
The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha (PDGFRα) is expressed and is driving the disease, and provides methods for identifying a mammalian NSCLC tumor that belongs to a subset of NSCLC tumors in which PDGFRα is expressed, and for identifying a NSCLC tumor that is likely to respond to a PDGFRα-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFRα is expressed, and for determining whether a compound inhibits the progression of a PDGFRα-expressing mammalian NSCLC tumor.
REFERENCES:
patent: 2006/0084142 (2006-04-01), Heinrich et al.
Zhang, Gao, Turner, and Ducatman. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Molecular Cancer, 2003. vol. 2, pp. 1-9.
Gerber, Rush, Stemman, Kirschner, and Gygi. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. PNAS, 2003. vol. 100, pp. 6940-6945.
Mendel, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting VEGF and PDGFR: determination of a pharmacokinetic/pharmodynamic relationship. Clinical Cancer Research, 2003. vol. 9, pp. 327-337.
Fitzer-Attas, Feldman, and Eisenbach. Expression of functionally intact PDGF-alpha receptors in highly metastatic 3LL Lewis lung carcinoma cells. International Journal of Cancer, 1993. vol. 53, pp. 315-322.
American Cancer Society, Cancer Facts and Figures 2003.
Ross, et al, Cell 46: 155-169 (1986).
Ross, et al, Adv. Exp. Med. Bio. 234: 9-21 (1988).
Gazit, et al, Cell 39: 89-97 (1984).
Heldin et al., Physiol. Rev. 79(4): 1283-1316 (1999).
Ide, et al., PNAS 99(22): 14404-14409 (2002).
Vassbotn, et al., J. Cell. Physiol. 158: 381-389 (1994).
Apperley, et al., N. Engl. J. Med. 347(7): 481-7 (2002).
Zhang, et al., Mol. Cancer 2(1): 1-10 (2003).
Vignaud, J.-M. et al., “The Role of Platelet-derived Growth Factor Production by Tumor-associated Macrophages in Tumor Stroma Formation in Lung Cancer”, Cancer Res. 54 (20): 5455-5463 (1994).
Forsberg, K. et al., Expression of Functional PDGF beta Receptors in a Human Large-Cell Lung-Carcinoma Cell Line, International Journal of Cancer 53(4): 556-560 (1993).
Laird, A. D. et al., “Mechanism of Action and Biomarker Studies of SU11248, a Selective Oral Multi-Targeted Tyrosine Kinase Inhibitor With Anti-Tumor and Anti-Angiogenic Activity Through Targeting PDGFR, VEGFR, KIT and FLT3”, Proc. of the American Assoc. for Cancer Res. vol. 44, 2ndEd., p. 937, Abstract #4716 (Jul. 2003).
Reinmuth, N. “Combined anti-PDGFR-α and PDGFR-β targeting in non-small cell lung cancer,” Int. J. Cancer 124:1535-1544 (2009).
Crosby Katherine
Guo Ailan
Lee Kimberly
Polakiewicz Roberto
Rikova Klarisa
Cell Signaling Technology, Inc.
Gussow Anne M.
Wilker Nancy Chiu
LandOfFree
Identification of non-small cell lung carcinoma (NSCLC)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Identification of non-small cell lung carcinoma (NSCLC)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Identification of non-small cell lung carcinoma (NSCLC)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2652352